Literature DB >> 25776074

Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism.

Fumitoshi Satoh1, Ryo Morimoto2, Yoshikiyo Ono2, Yoshitsugu Iwakura2, Kei Omata2, Masataka Kudo2, Kei Takase2, Kazumasa Seiji2, Hidehiko Sasamoto2, Seijiro Honma2, Mitsunobu Okuyama2, Kouwa Yamashita2, Celso E Gomez-Sanchez2, William E Rainey2, Yoichi Arai2, Hironobu Sasano2, Yasuhiro Nakamura2, Sadayoshi Ito2.   

Abstract

Adrenal venous sampling is currently the only reliable method to distinguish unilateral from bilateral diseases in primary aldosteronism. In this study, we attempted to determine whether peripheral plasma levels of 18-oxocortisol (18oxoF) and 18-hydroxycortisol could contribute to the clinical differentiation between aldosteronoma and bilateral hyperaldosteronism in 234 patients with primary aldosteronism, including computed tomography (CT)-detectable aldosteronoma (n=113) and bilateral hyperaldosteronism (n=121), all of whom underwent CT and adrenal venous sampling. All aldosteronomas were surgically resected and the accuracy of diagnosis was clinically and histopathologically confirmed. 18oxoF and 18-hydroxycortisol were measured using liquid chromatography tandem mass spectrometry. Receiver operating characteristic analysis of 18oxoF discrimination of adenoma from hyperplasia demonstrated sensitivity/specificity of 0.83/0.99 at a cut-off value of 4.7 ng/dL, compared with that based on 18-hydroxycortisol (sensitivity/specificity: 0.62/0.96). 18oxoF levels above 6.1 ng/dL or of aldosterone >32.7 ng/dL were found in 95 of 113 patients with aldosteronoma (84%) but in none of 121 bilateral hyperaldosteronism, 30 of whom harbored CT-detectable unilateral nonfunctioning nodules in their adrenals. In addition, 18oxoF levels below 1.2 ng/dL, the lowest in aldosteronoma, were found 52 of the 121 (43%) patients with bilateral hyperaldosteronism. Further analysis of 27 patients with CT-undetectable micro aldosteronomas revealed that 8 of these 27 patients had CT-detectable contralateral adrenal nodules, the highest values of 18oxoF and aldosterone were 4.8 and 24.5 ng/dL, respectively, both below their cut-off levels indicated above. The peripheral plasma 18oxoF concentrations served not only to differentiate aldosteronoma but also could serve to avoid unnecessary surgery for nonfunctioning adrenocortical nodules concurrent with hyperplasia or microadenoma.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  1-(2-(18F)fluoro-3-pyridyl)-4-(2-isopropyl-1-oxo-isoindoline-5-yl)-5-methyl-1H-1,2,3-triazole; hyperaldosteronism

Mesh:

Substances:

Year:  2015        PMID: 25776074      PMCID: PMC4642692          DOI: 10.1161/HYPERTENSIONAHA.114.04453

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  32 in total

1.  Clinical characteristics of aldosterone-producing microadenoma, macroadenoma, and idiopathic hyperaldosteronism in 93 patients with primary aldosteronism.

Authors:  Masao Omura; Hironobu Sasano; Jun Saito; Kunio Yamaguchi; Yukio Kakuta; Tetsuo Nishikawa
Journal:  Hypertens Res       Date:  2006-11       Impact factor: 3.872

2.  Role for adrenal venous sampling in primary aldosteronism.

Authors:  William F Young; Anthony W Stanson; Geoffrey B Thompson; Clive S Grant; David R Farley; Jon A van Heerden
Journal:  Surgery       Date:  2004-12       Impact factor: 3.982

3.  Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.

Authors:  Paul Milliez; Xavier Girerd; Pierre-François Plouin; Jacques Blacher; Michel E Safar; Jean-Jacques Mourad
Journal:  J Am Coll Cardiol       Date:  2005-04-19       Impact factor: 24.094

4.  The utility of three different methods for measuring urinary 18-hydroxycortisol in the differential diagnosis of suspected primary hyperaldosteronism.

Authors:  R M Reynolds; L A Shakerdi; K Sandhu; A M Wallace; P J Wood; B R Walker
Journal:  Eur J Endocrinol       Date:  2005-06       Impact factor: 6.664

5.  Production of 18-oxo-cortisol in subtypes of primary aldosteronism.

Authors:  M Stowasser; A W Bachmann; T J Tunny; R D Gordon
Journal:  Clin Exp Pharmacol Physiol       Date:  1996 Jun-Jul       Impact factor: 2.557

6.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

7.  Primary aldosteronism--careful investigation is essential and rewarding.

Authors:  Michael Stowasser; Richard D Gordon
Journal:  Mol Cell Endocrinol       Date:  2004-03-31       Impact factor: 4.102

8.  The unique steroidogenesis of the aldosteronoma in the differential diagnosis of primary aldosteronism.

Authors:  S Ulick; J D Blumenfeld; S A Atlas; J Z Wang; E D Vaughan
Journal:  J Clin Endocrinol Metab       Date:  1993-04       Impact factor: 5.958

9.  A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension.

Authors:  R P Lifton; R G Dluhy; M Powers; G M Rich; S Cook; S Ulick; J M Lalouel
Journal:  Nature       Date:  1992-01-16       Impact factor: 49.962

10.  Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol.

Authors:  P Mulatero; K M Curnow; B Aupetit-Faisant; M Foekling; C Gomez-Sanchez; F Veglio; X Jeunemaitre; P Corvol; L Pascoe
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958

View more
  41 in total

Review 1.  Familial hyperaldosteronism type III a novel case and review of literature.

Authors:  Natividad Pons Fernández; Francisca Moreno; Julia Morata; Ana Moriano; Sara León; Carmen De Mingo; Ángel Zuñiga; Fernando Calvo
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

2.  Histopathological Classification of Cross-Sectional Image-Negative Hyperaldosteronism.

Authors:  Yuto Yamazaki; Yasuhiro Nakamura; Kei Omata; Kazue Ise; Yuta Tezuka; Yoshikiyo Ono; Ryo Morimoto; Yukinaga Nozawa; Celso E Gomez-Sanchez; Scott A Tomlins; William E Rainey; Sadayoshi Ito; Fumitoshi Satoh; Hironobu Sasano
Journal:  J Clin Endocrinol Metab       Date:  2017-04-01       Impact factor: 5.958

Review 3.  The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment.

Authors:  Anand Vaidya; Paolo Mulatero; Rene Baudrand; Gail K Adler
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

Review 4.  Steroid Profiling and Immunohistochemistry for Subtyping and Outcome Prediction in Primary Aldosteronism-a Review.

Authors:  Finn Holler; Daniel A Heinrich; Christian Adolf; Benjamin Lechner; Martin Bidlingmaier; Graeme Eisenhofer; Tracy Ann Williams; Martin Reincke
Journal:  Curr Hypertens Rep       Date:  2019-09-03       Impact factor: 5.369

Review 5.  Hyperaldosteronism: How to Discriminate Among Different Disease Forms?

Authors:  Valentina Crudo; Silvia Monticone; Jacopo Burrello; Fabrizio Buffolo; Martina Tetti; Franco Veglio; Paolo Mulatero
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-05-02

Review 6.  Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

Authors:  Elise P Gomez-Sanchez
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

Review 7.  Primary aldosteronism is a public health issue: challenges and opportunities.

Authors:  Renata Libianto; Peter J Fuller; Morag J Young; Jun Yang
Journal:  J Hum Hypertens       Date:  2020-04-27       Impact factor: 3.012

Review 8.  Primary Aldosteronism: Practical Approach to Diagnosis and Management.

Authors:  James Brian Byrd; Adina F Turcu; Richard J Auchus
Journal:  Circulation       Date:  2018-08-21       Impact factor: 29.690

Review 9.  Steroid biomarkers in human adrenal disease.

Authors:  Juilee Rege; Adina F Turcu; Tobias Else; Richard J Auchus; William E Rainey
Journal:  J Steroid Biochem Mol Biol       Date:  2019-01-29       Impact factor: 4.292

Review 10.  DIAGNOSIS OF ENDOCRINE DISEASE: 18-Oxocortisol and 18-hydroxycortisol: is there clinical utility of these steroids?

Authors:  Jacques W M Lenders; Tracy Ann Williams; Martin Reincke; Celso E Gomez-Sanchez
Journal:  Eur J Endocrinol       Date:  2017-09-13       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.